Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Hydromethylthionine mesylate by TauRx Pharmaceuticals for Alzheimer's Disease: Likelihood of Approval
Hydromethylthionine mesylate is under clinical development by TauRx Pharmaceuticals and currently in Phase III for Alzheimer's Disease. According to GlobalData,...